Trial Profile

A Prospective, Randomized, Multi-center Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization in a Population of Unrestricted Patients.

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 17 Mar 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary)
Indications Coronary artery disease; Coronary artery restenosis
Focus Registrational; Therapeutic Use
Acronyms PLATINUM PLUS; PLATINUM+; PLATINUM-PLUS

Most Recent Events

02 Mar 2012 Planned End Date added to 1 Mar 2014 as reported by ClinicalTrials.gov.
02 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
26 Apr 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com